🌅 Morning Brief — Monday, August 10, 2026

Market Overview

The S&P 500 is coming off its strongest week since April after July nonfarm payrolls came in at -23,000 — a genuine shocker that took Fed rate hike odds off the table entirely and triggered a relief rally across rate-sensitive and growth names. Biotech and tech led Friday’s surge, with multiple earnings beats compounding the macro tailwind. This morning, equity futures are mixed with SPY down 0.1% as rising oil prices introduce a modest headwind, but the underlying sentiment remains constructive with earnings season delivering broadly positive results — S&P 500 Q2 profits described as “booming.”

Claude’s Call

UP — The macro setup remains a tailwind: rate hike fears are dead for now, earnings season is running hot, and Friday’s momentum hasn’t fully priced in yet for names that moved late in the session. Watch for rotation into energy (oil spike) as a secondary theme, but the growth/biotech complex holds the baton today.

Top Movers

ABCL (+23.4%) — $8.55 → $10.48 (+22.6% upside) Thesis: This is a real, binary catalyst — ABCL-635 hit primary endpoints in Phase 2, slashing menopausal hot flash frequency by 83% with a single dose vs. placebo. That’s not a marginal win; that’s a potential class-defining result in a massive underserved market. The stock is at its 6-month high and well above the 50 SMA ($6.25), but the fib 1.272 extension at $10.48 gives you a legitimate target before the next resistance zone. With valuation comps flagging ABCL as CHEAP despite 96% revenue growth and a pipeline event this size, the risk/reward still tilts bullish intraday. Levels: Exit at fib 1.272 extension $10.48. Support at fib 23.6% $7.47; below that, the SMA-50 at $6.25 is the line in the sand.

NTRA (+21.4%) — $322.10 → $360.03 (+11.8% upside) Thesis: Natera is firing on all cylinders — record Signatera test volumes, raised 2026 revenue guidance to $2.85B–$2.91B, and a fresh Japan companion diagnostic filing. This is a secular winner in liquid biopsy that just confirmed its commercial acceleration isn’t slowing. Technically, NTRA is at its 6-month high and already 26% above its 50 SMA ($254.66), so this isn’t a cheap entry — but the fib 1.272 extension at $360 gives reasonable near-term upside if the momentum holds. The shelf filing (dilution risk) is the key overhang to monitor. Levels: Exit at fib 1.272 extension $360.03. Support at fib 23.6% $289.19; deeper support at $252.38 (fib 50%).

HALO (+20.2%) — $103.12 → $114.94 (+11.5% upside) Thesis: Halozyme’s ENHANZE platform delivered a 48% YoY revenue surge to $481M in Q2, raised full-year guidance to $1.84B–$1.91B, and completed $750M in buybacks while initiating a new repurchase program. Five new partnerships signed in the quarter — this is a royalty engine compounding at a serious clip. Valuation comps show HALO at 10x forward P/E vs. peer median of 14.3x with 47.7% revenue growth — that’s genuinely cheap on a PEG basis. At the 6-month high with 1.272 fib at $114.94, there’s still a clean setup here. Levels: Exit at fib 1.272 extension $114.94. Support at fib 23.6% $93.65; deeper at $87.53 (fib 38.2%).

FIVN (+19.8%) — $33.99 → $39.53 (+16.3% upside) Thesis: Five9 beat Q2 revenue guidance and reported 78% AI revenue growth — that’s not incremental, that’s a transformation signal. Subscription revenue up 14% YoY for the third consecutive quarter of acceleration. The company raised its full-year AI revenue outlook to “at least 60% growth.” Contact center AI is a genuine secular theme and Five9 is executing. Valuation screams CHEAP — 8.5x forward P/E vs. peer median of 40x. Yes, growth is only 10% on the headline, but the AI mix shift is what matters here. Levels: Exit at fib 1.272 extension $39.53. Support at fib 23.6% $29.18; SMA-50 at $24.23 is the fortress below.

ABNB (+17.4%) — $178.07 → $196.89 (+10.6% upside) Thesis: Airbnb beat Q2 revenue estimates with sales up 16.5% YoY to $3.61B and non-GAAP EPS of $1.37 — 10% above consensus. The CEO is publicly crediting AI as driving “fastest growth in years” and there’s apparently a secret internal AI lab. This is a large-cap name breaking to 52-week highs on real fundamental acceleration, not hype. At the 6-month high with volume confirmation, the fib 1.272 at $196.89 is achievable. The one caveat: at $178 you’re already 23% above the 50 SMA ($144.41) so this is momentum-chasing territory. Levels: Exit at fib 1.272 extension $196.89. Support at fib 23.6% $164.57; 50 SMA $144.41 is the ultimate floor.

ROAD (+19.6%) — $119.74 → $153.26 (+27.9% upside) Thesis: Construction Partners crushed Q3 with 28.2% revenue growth to $999M, record backlog, raised full-year guidance, and announced a strategic push into data center construction — that last point is the kicker that expands the multiple. RSI is at a deeply oversold 9.6 (yes, really), which is extraordinary for a stock up 20% today — suggesting this is a violent snap-back from an extremely depressed base. The stock had fallen 28.7% over the prior 90 days despite strong fundamentals. This looks like capitulation reversal, not a momentum chase. Levels: Exit at fib 1.272 extension $153.26. Support at fib 50% $116.99 and SMA-50 $109.67.

QNST (+38.5%) — $21.08 → $25.17 (+19.4% upside) Thesis: QuinStreet set all-time records for Q4 revenue and net income — 43% YoY revenue growth with 87% EBITDA expansion. Home services vertical up 88%, auto insurance roaring back. EPS beat by 13.6%, revenue beat by 3.9%. This is a genuine earnings blowout in a performance marketing name that was left for dead. At the 6-month high with fib 1.272 at $25.17, momentum players have a clean target. However, with a 38.5% single-day move and volume ratio at a paltry 0.16x average, be cautious — thin volume on a big move raises questions about durability. Levels: Exit at fib 1.272 $25.17. Support at fib 23.6% $19.33; deeper at $17.66 (fib 38.2%).

CRSR (+35.3%) — $14.35 → $17.01 (+18.5% upside) Thesis: Corsair Gaming posted “convincing beats” on Q2 estimates with higher gross margins, improved profitability, substantially stronger operating cash flow, and raised full-year 2026 guidance. Analysts lifted fair value estimates from $8.81 to $10.22 — and the stock is already at $14.35, suggesting the market is pricing in even more upside than the models show. At 6-month highs with fib 1.272 at $17.01, there’s still runway, but a 35% single-day move with volume at only 0.19x average is a yellow flag. This feels more like a short squeeze on top of a real beat. Levels: Exit at fib 1.272 $17.01. Support at fib 23.6% $12.04; 50 SMA $9.84 is the deeper floor.

AXTI (+17.8%) — $88.58 → Caution — overextended Thesis: AXT’s indium phosphide revenue surged 164% driven by AI data center demand, and a long-term supply deal with Lumentum (up to $87.5M in deposits) de-risks the revenue stream. Needham upgraded to Buy at $90 target. This is a genuine picks-and-shovels AI play in a critical materials bottleneck. BUT — AXTI is sitting below its 6-month high of $140.83 but within striking distance of the fib 38.2% retracement level ($95.90), meaning this bounce is still finding its footing after a steep correction. Vol ratio is only 0.13x. More of a hold-and-watch situation today. Levels: Exit resistance at fib 38.2% $95.90. Support at fib 50% $82.02; 50 SMA $71.82 below.

FLR (+16.9%) — $57.00 → $60.94 (+6.9% upside) Thesis: Fluor crushed Q2 — revenue $4.3B (+9% YoY), adjusted EBITDA more than doubled to $149M from $96M, and the backlog climbed to $26.9B on $6B+ in new awards. Adding a retired Navy Admiral with nuclear expertise to the board as it expands into nuclear construction is a strategic signal, not a press release filler. RSI at 13.23 confirms this was a deeply oversold name before the catalyst — the reversal has real conviction. Infrastructure + nuclear is a multi-year secular theme. At the 6-month high, fib 1.272 at $60.94 is the near-term target. Levels: Exit at fib 1.272 $60.94; fib 1.618 $65.94 for the bulls. Support at fib 23.6% $53.59.

Headlines to Watch

S&P 500 Ends At Record High, Clocks Strongest Week Since April As Poor Jobs Data Calms Rate Hike Fear — Nonfarm payrolls at -23,000 removes the Fed tightening overhang entirely; this is the single most important macro backdrop supporting today’s continuation bid in growth names.
Airbnb CEO: “Why AI is the best thing to happen to us” — A large-cap CEO publicly crediting AI for fastest growth in years, plus confirming a secret AI lab, could re-rate ABNB as a tech/AI name vs. just travel — watch for multiple expansion.
ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial — Single-dose efficacy in a $10B+ underserved market; if Phase 3 replicates, this could be transformative. Today’s 23% move may be the beginning, not the end.
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Monday Amid Rising Oil Prices — Rising oil is a double-edged sword: good for NESR and SCCO (energy/materials), but a tax on consumer discretionary and transportation names — monitor sector rotation signals.
S&P 500 Companies’ Second-Quarter Profit Boomed — What’s Next? — The earnings season is structurally bullish, but “what’s next” is the right question — with the Fed on hold, the next catalyst is either re-acceleration or guidance disappointment in Q3. Position accordingly.
Super Micro Computer Continues Its 3-Month Fall — SMCI is down a third from its highs while AI server peers hit records — this is either the contrarian buy of the year or a structural share-loss story. One Wall Street bull sees 55% upside; the chart says “falling knife.” Don’t catch it today.
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks — ABCL’s hot flash data plus positive oncology and cardiac trial readouts broadly suggests the biotech sector is re-rating; HALO and NTRA benefit from this rising tide.

Claude’s Top Picks

HALO (+20.2% today, +24.9% week) — $103.12 → $114.94 (+11.5% upside) Valuation: CHEAP — Forward P/E of 10x vs. peer median 14.3x with 47.7% revenue growth; PEG ratio is well below 1, making this one of the most compelling risk-adjusted setups in the large-cap biotech space. Upside: Five new partnerships, accelerating ENHANZE royalties, $750M+ in completed buybacks, and a second growth engine (Hypercon) in development — this has multiple legs beyond Q2. Risk: Royalty concentration risk — if a key pharma partner delays a product launch, royalty revenue can disappoint sharply; watch any partner-specific pipeline news.

FIVN (+19.8% today, +23.6% week) — $33.99 → $39.53 (+16.3% upside) Valuation: CHEAP — 8.5x forward P/E vs. peer median of 40x in cloud software; the market is pricing this as a dying legacy CCaaS name, but the 78% AI revenue growth says otherwise. Upside: AI revenue mix shift is compounding faster than the market anticipated, and the Fortune 100 win signals enterprise credibility — re-rating toward software peers could close a multi-turn valuation gap. Risk: Overall revenue growth of only 10% means any deceleration in the AI segment or increased competitive pressure from AWS/Google Contact Center AI could cause the multiple to stagnate rather than expand.

ROAD (+19.6% today, +15.9% week) — $119.74 → $153.26 (+27.9% upside) Valuation: No comp data provided, but a 28% revenue grower with record backlog entering the data center construction vertical deserves a premium to traditional infrastructure names. Upside: RSI of 9.6 pre-bounce signals this was maximum pessimism territory; combined with a genuine earnings beat and the data center expansion angle, the mean-reversion setup here is among the cleanest on the board. Risk: Data center construction is a new vertical — execution risk is real, and if the broader infrastructure spending cycle cools, ROAD’s backlog growth rate becomes the key watch item.

ABCL (+23.4% today, +46.7% week) — $8.55 → $10.48 (+22.6% upside) Valuation: CHEAP on comps (though pre-profit), with 96% revenue growth and a pipeline asset that just delivered best-in-class Phase 2 efficacy data; the market is still not fully pricing a commercial-stage outcome. Upside: 83% hot flash reduction with a single dose is a genuinely differentiated profile versus the hormonal and CGRP-class competition — if Phase 3 is initiated swiftly, the stock re-rates to pipeline value, not cash burn value. Risk: Phase 2 to Phase 3 attrition is brutal in CNS/endocrine; four-week data is encouraging but long-duration safety and durability data doesn’t exist yet — any hint of a mixed signal in extended follow-up collapses the thesis.

FLR (+16.9% today, +13.6% week) — $57.00 → $60.94 (+6.9% upside) Valuation: Engineering & construction peers trade at 10–14x EV/EBITDA; Fluor’s EBITDA more than doubled in Q2 and backlog is at multi-year highs, suggesting the stock still has room to re-rate even after Friday’s move. Upside: Nuclear infrastructure is a 10-year secular theme, the $26.9B backlog provides multi-year revenue visibility, and the deeply oversold RSI (13.23 pre-bounce) means institutional buyers who were underweight are still catching up. Risk: Fluor has a history of project execution surprises and cost overruns — any large fixed-price contract going sideways can wipe out several quarters of earnings guidance instantly.

Avoid

GENVR (+55.7% today, +233.9% week) — The ticker data appears to reference Gen Digital (GEN) news incorrectly, but the technical setup is alarming regardless: up 233% in a week at its 6-month high with SMA-50 at $1.73 vs. current price of $3.94. The vol ratio is 12.93x average — this is pure momentum/squeeze territory with zero fib extension room below before a cliff. Chasing after a 233% weekly move with no identifiable company-specific catalyst tied to the GENVR ticker is a reliable way to be the exit liquidity.

CRSR (+35.3%) — The earnings beat is real, but a 35% single-day gap on 0.19x average volume is the definition of a low-conviction squeeze. Analysts only lifted fair value to $10.22 — the stock is trading 40% above that new target already. The gaming peripherals market is cyclically challenged, and when this thin volume dries up, there’s a long way back to the 50 SMA at $9.84.

QNST (+38.5%) — Again, the earnings beat is genuine (43% revenue growth is real), but a 38.5% single-day move on 0.16x average volume is a massive red flag. You’re buying a stock at its 6-month high after it’s already moved nearly 40% today on paper-thin volume. The 23.6% fib retracement support is at $19.33 — a normal 2-day mean reversion erases most of today’s gain. Wait for consolidation.

WSB Sentiment Check

HTZ — WSB says: BULLISH (80% bullish, 188 mentions, 1,140 upvotes) Claude says: DISAGREE — HTZ is at $2.49 with its 50 SMA at $3.06 and the 6-month high at $7.81; the chart is in freefall — sitting 68% below the 6-month high with every fib retracement level ($3.92, $4.66, $5.40, $6.32) acting as overhead resistance. WSB loves a bankrupt/near-bankrupt car rental narrative, but the EV fleet write-down story isn’t resolved and there is no identified near-term catalyst. This is hopium with a distressed balance sheet — 80% bullish on a chart this broken is a contrarian sell signal.

SPCX — WSB says: BULLISH (80% bullish, 111 mentions, 280 upvotes) Claude says: PARTIALLY — SPCX (Space ETF) at $132 is sitting 37% below its 6-month high of $211.39, and every fib level ($147–$187) is overhead resistance. The SpaceX earnings call ripple effect is real (see RKLB and ASTS) and the space theme is a legitimate secular story. However, SPCX as a vehicle is below all meaningful technical support — you’re buying into a broken chart on SpaceX coattails. Better to own RKLB or ASTS directly if you believe the theme.

MU — WSB says: BULLISH (80% bullish, 104 mentions, 444 upvotes) Claude says: PARTIALLY — MU at $864 is in a technically difficult spot: below the 50 SMA ($969), 6-month high of $1,213, and sitting right on the fib 38.2% support at $872. The HBM/AI memory thesis is real and the long-term bull case is intact, but right now MU is in a correction within a bull market. The fib support at $767 is the next real test if $872 breaks. WSB isn’t wrong on the thesis, just potentially early on the timing — wait for a reclaim of the 50 SMA before loading.

RKLB — WSB says: BULLISH (80% bullish, 85 mentions, 250 upvotes) Claude says: PARTIALLY — RKLB reported yesterday (EPS: -$0.32, reaction +1.9%), and revenue grew 63% but the stock is down 30% from its highs, trading at $83.57 vs. 6-month high of $150.23. The SpaceX call creating ripple effects is the near-term catalyst, but RKLB is below its 50 SMA ($89.26) and all major fib retracements are well overhead ($92–$128). Analyst target is $111 — that’s 33% upside from here, which is attractive if you believe the Neutron development timeline. The WSB thesis has merit but the chart needs to reclaim $89 (50 SMA) to confirm.

ASTS — WSB says: BULLISH (80% bullish, 55 mentions, 161 upvotes) Claude says: DISAGREE — ASTS reported yesterday (EPS: -$1.80, reaction -1.0% despite a bullish pre-earnings setup), and the chart is trading at $71 — well below the 6-month high of $133 with every fib retracement ($83–$114) overhead. The satellite-to-cellular story is visionary but pre-revenue, cash-burning, and the negative post-earnings reaction despite retail optimism is a warning sign. Analyst target of $80.48 implies modest upside, but with a dilution risk and no near-term commercial revenue, the risk/reward doesn’t justify 80% bullish conviction. Speculative position sizing only.

Earnings Scorecard

LITE (Lumentum) — REPORTED | Stock: +5.0% | EPS: $5.70 The muted +5% reaction to what appears to be a solid print is interesting — expectations were likely high given the AI photonics narrative and AXT’s (AXTI) indium phosphide deal with Lumentum. The reaction is justified but underwhelming; the market is not re-rating Lumentum as an AI darling yet. Hold — not a buy-the-dip or sell-the-rip situation; consolidation likely.

SMCI (Super Micro Computer) — REPORTED | Stock: +2.5% | EPS: $1.90 SMCI reported $60B in orders last quarter and the stock barely moved — that’s a supply credibility and margin trust issue, not a demand problem. The muted reaction despite monster order flow confirms institutional skepticism about execution and balance sheet quality. Avoid — the reaction is insufficient relative to the order magnitude; something is structurally wrong with the story that the market is pricing in.

RKLB (Rocket Lab) — REPORTED | Stock: +1.9% | EPS: -$0.32 Revenue grew 63% but EPS of -$0.32 on a pre-revenue launch company isn’t surprising. The +1.9% reaction is underwhelming given 63% growth — the market wanted Neutron timeline updates and may have been disappointed. Watch — not a buy-the-dip yet; needs to reclaim $89 (50 SMA) first.

HIMS (Hims & Hers) — REPORTED | Stock: -1.6% | EPS: -$0.09 The minor decline on what appears to be a near-breakeven EPS print in a high-growth telehealth name suggests the market was expecting more of an inflection toward profitability. Analyst target of $29.23 implies 80%+ upside from implied current levels — the reaction looks overdone to the downside. Potential buy-the-dip candidate for speculative accounts.

COHR (Coherent Corp) — REPORTED | Stock: +1.4% | EPS: $2.09 Coherent is an AI photonics and datacom play with a $394 analyst target. The muted +1.4% reaction with a $2.09 EPS print likely reflects a “meet, not beat” scenario. Hold — no urgency either direction.

AMAT (Applied Materials) — REPORTED | Stock: +1.1% | EPS: $10.62 A $10.62 EPS print with only a 1.1% reaction for a semiconductor equipment giant suggests the beat was already priced in. Analyst target of $629 implies meaningful upside from wherever shares currently trade. Hold — not actionable today.

ASTS (AST SpaceMobile) — REPORTED | Stock: -1.0% | EPS: -$1.80 Pre-earnings retail optimism evaporated on the print. The -1.0% reaction despite 80% WSB bullishness is a reality check — EPS of -$1.80 with no commercial revenue path imminent is a speculative hold at best. Reaction was justified — don’t fight the tape on this one.

NBIS (Nebius) — REPORTED | Stock: -0.6% | EPS: $2.59 Analyst target of $250.75 vs. implied current pricing suggests massive upside, but the marginal negative reaction indicates the AI cloud build-out thesis needs to be proven through contracted demand converting to profits. Monitor — too early to act.

This brief is for informational purposes only and does not constitute investment advice. All prices and levels reference data as of market close August 8 / pre-market August 10, 2026.